



北京大学医学部
PEKING UNIVERSITY HEALTH SCIENCE CENTER



PUHSC-SSSTC Joint Symposium on Cancer and Neuroscience

Organized by
Peking University Health Science Center
Sino Swiss Science and Technology Cooperation

October 14-17, 2013
Beijing • China



BASIC INFORMATION

Venues: Peking University Health Science Center (38 Xue Yuan Road, Beijing)

Peking University Cancer Hospital (52 Fu Cheng Road, Beijing)

Hosts: Peking University Health Science Center (PUHSC)

Sino Swiss Science and Technology Cooperation (SSSTC)

Local-Organizers: Office of International Cooperation (OIC), PUHSC

Neuroscience Research Institute, Peking University

Peking University Cancer Hospital

Secretariats: Dr. Maio Su Chen, SSSTC, ETH Zurich, Switzerland

Dr. Lei Zhang, Associate Director, Office of International Cooperation, PUHSC



NOTE FOR SPEAKERS

Welcome to Beijing for PUHSC-SSSTC Joint Symposium on Cancer and Neuroscience! The symposium will consist of one-and-a-half-day presentations and discussions, followed by visitations and social events. Detailed arrangement is included in the symposium brochure. For assistance, please contact Dr. Lei Zhang @ +86 134 3670 6993 or Mr. Yuan Liu @ +86 188 1077 5516. Wish you a pleasant stay in Beijing!

ARRIVAL IN BEIJING

Airport Pick-up

Airport pick-up service will be arranged according to flight details provided for speakers pre-arranging pick-up service with us.

WEATHER

The average temperature during October 14-17 is 15 °C during the day and 5 °C in the evenings. We recommend that you bring warm clothes with you.

ACCOMMODATION

Vision Hotel

39 Xue Yuan Road, Beijing

T: +86 10 6230 8899 | +86 10 8233 8889

F: +86 10 6230 8816

<http://www.visionplaza.cn>

NOTE: *The hotel is only ten-minute-walk from PUHSC. We will provide you with accommodation (breakfast included) from October 14-17 (SSSTC will bear the local cost of the young researchers). Other expenses at the hotel should be paid on your own account.*

The following map marks the locations of Vision Hotel and PUHSC with “A” and “B”, respectively.



BREAKFAST, LUNCH AND DINNER

Breakfast will be provided by the hotel. Lunch and dinner will be provided to meeting attendees as specified in the meeting schedule.

Please note that meals outside of the official schedule are the responsibility of each attendee.

TRANSPORTATION DURING SYMPOSIUM

Transportation will be provided to and from Vision Hotel, dinner and meeting venues. Please meet in the hotel lobby, unless otherwise specified in the program, 5 minutes prior to the designated departure time.

Please refer to the tentative timetable below.

OCTOBER 14, 2013		
PICK-UP TIME	FROM	TO
17:00	Vision Hotel	La Source (dinner)
20:00	La Source (dinner)	Vision Hotel
OCTOBER 15, 2013		
07:40	Vision Hotel	PUHSC
08:50	PUHSC	Cancer Hospital*
17:30	PUHSC	Vision Hotel (Walk)
17:50	Cancer Hospital*	Vision Hotel
OCTOBER 16, 2013		
08:40	Vision Hotel	PUHSC
07:40	Vision Hotel	Cancer Hospital*
13:30	PUHSC	Forbidden City
	Cancer Hospital*	Forbidden City
17:30	Forbidden City	Quanjudé (dinner)
20:30	Quanjudé (dinner)	Vision Hotel
OCTOBER 17, 2013		
08:00	Vision Hotel**	Great Wall
12:30	Great Wall***	Airport

*Peking University Cancer Hospital: only for cancer group

**Please check-out and put your luggage on the bus before heading to the Great Wall

***Lunch box will be provided

SCHEDULE AND PROGRAM

SUNDAY, OCTOBER 13, 2013

	Airport Pick-up (CA862 12:55 Terminal 3) Contact Person: Limin Mu +86 152 0146 9347	Arranged by OIC
	Hotel Check-in Vision Hotel (39 Xue Yuan Road, Beijing, T: +86 10 6230 8899, +86 10 8233 8889, F: +86 10 6230 8816, www.visionplaza.cn)	

MONDAY, OCTOBER 14, 2013

	Airport Pick-up (LX196 05:15 Terminal 3) Contact Person: Jiantao He +86 182 1059 9332	Arranged by OIC
	Hotel Check-in Vision Hotel	
17:00	Hotel Pick-up Yuan Liu (+86 188 1077 5516) will meet the delegation at the hotel lobby	
17:00-18:00	Transfer to La Source Restaurant (Banchang Hutong)	
18:00-20:00	Dinner at La Source Restaurant Host: Swiss Embassy in the People's Republic of China	
20:00	Back to Vision Hotel	

TUESDAY, OCTOBER 15, 2013

07:40	Hotel Pick-up Yuan Liu (+86 188 1077 5516) will meet the delegation at the hotel lobby	
07:40-08:00	Transfer to PUHSC (All Delegates)	
08:00-08:50	Opening Ceremony Venue: Room 209 Yifu Building at PUHSC (38 Xue Yuan Road, Beijing) Chair: Prof. Weigang Fang , Vice President, PUHSC Opening Remarks: Prof. Yang Ke Executive Vice President, Peking University and PUHSC Mrs. Salome Meyer Minister & Deputy Head of Mission, Swiss Embassy in the People's Republic of China Dr. Maio Su Chen (Message from the Ministry of Education, Switzerland) Program Manager, SSSTC, ETH Global Group Photo <i>(Cancer group leaves for Peking University Cancer Hospital; Neuroscience group stays in the same venue)</i>	
08:50-09:00	Break	
09:00-17:50	Neuroscience Session Venue: Room 209 Yifu Building, PUHSC <i>(refer to pp.4-5 for details)</i>	Cancer Session Venue: 3rd Conference Room, 4th Floor, Scientific Research Building, Peking University Cancer Hospital <i>(refer to pp.6-7 for details)</i>
18:50-21:00	Welcome Banquet- Invited Only Place: Tai Shan Banquet Hall at Vision Hotel (Second Floor)	

NEUROSCIENCE SESSION ON TUESDAY, OCTOBER 15, 2013

Venue: Room 209 Yifu Building at PUHSC

	5 Presentations: 30 min/speech (20 min presentation & 10 min Q&A)			
	TITLE	CHAIRS	SPEAKER	
09:00-11:30	Evolution of Prions	Prof. Albert Cheung-Hoi Yu Prof. Adriano Aguzzi	Prof. Charles Weissmann	
	Specialization in Astrocytes Involved in Glutamate-Elicited Responses		Prof. Albert Cheung-Hoi Yu	
	Metabolic Control of Adult Neural Stem Cell Activity		Prof. Sebastian Jessberger	
	Targeting Voltage-Gated Kv7/KCNQ K ⁺ Channels for Therapeutic Potential of Neuropsychiatric Disorders		Prof. Kewei Wang	
	Synaptic Transneuronal Propagation of Mutant Huntington Exacerbates Non-Cell Autonomous Pathology in Neurons		Dr. Tewis Bouwmeester	
12:00-13:00	Lunch (lunch box will be provided)			
	7 Presentations: 30min/speech (20min presentation & 10 min Q&A)			
	TITLE	CHAIRS	SPEAKER	
13:30-17:30	Mechanisms of Pathological Emotional Memory: From Animal to Human	Dr. Ann Yuen Kwan Wong Dr. Tewis Bouwmeester	Prof. Lin Lu	
	Selective Targeting of APP Processing by Gamma-Secretase for the Treatment of Alzheimer's Disease		Assist. Prof. Patrick Fraering	
	Chemical Biology of α -Synuclein: The Role Post-Translational Modification in the Pathogenesis of Parkinson's Disease & Related Disorders		Assoc. Prof. Hilal Lashuel	
	Introduction of ALS Research of Peking University Third Hospital (PUTH)		Prof. Dongsheng Fan	
	Coffee Break			
	Age-Related Mitochondrial Dysfunction in Parkinson's Disease: A Role for PGC-1 Activity?		Dr. Ann Yuen Kwan Wong Dr. Tewis Bouwmeester	Dr. Bernard Schneider
<i>NIPA2</i> Located in 15q11.2 Play a Role in the Pathogenesis of Childhood Absence Epilepsy	Prof. Yuwu Jiang			
VTA GABA Cells Drive Specific Learning Behaviors via the Control of Two Neuromodulatory Systems	Dr. Kelly Tan			
17:30	Walk to Vision Hotel			

NEUROSCIENCE SESSION ON WEDNESDAY, OCTOBER 16 2013

Venue: Room 209 Yifu Building at PUHSC

08:40	Hotel Pick-up Yuan Liu (+86 188 1077 5516) will meet the delegation at the hotel lobby		
09:00-11:30	5 Presentations: 30 min/speech (20 min presentation & 10 min Q&A)		
	TITLE	CHAIRS	SPEAKER
	Mechanisms of Prion-Induced Toxicity	Prof. Xue-Jun Song	Prof. Adriano Aguzzi
	EphrinB-EphB & WNT Signaling: A New Avenue to Understanding and Treating Neuropathic and Cancer Pain	Prof. Bernard Schneider	Prof. Xuejun Song
	Protein Kinases and Pain Modulation		Prof. Yun Wang
	Inappropriate Enteric Lymphotoxin Receptor Signaling Causes Iron-Deficient Anemia		Dr. Caihong Zhu
	Cell Types, Circuits and Repair of the Visual System		Dr. Botond Roska
11:30-12:00	Closing Remarks		
12:00-13:00	Lunch (lunch box will be provided)		
13:30	Transfer to Forbidden City from PUHSC (refer to p.8 for details)		

CANCER SESSION ON TUESDAY, OCTOBER 15, 2013

Venue: 3rd Conference Room, 4th Floor, Scientific Research Building, Peking University Cancer Hospital

08:50-09:40	Transfer to Peking University Cancer Hospital		
9:50-10:00	Welcome Speech by Prof. Jiafu Ji, President of Peking University Cancer Hospital		
10:00-12:00	4 Presentations: 30 min/speech (20 min presentation & 10 min Q&A)		
	TITLE	CHAIRS	SPEAKER
	Neural Crest Stem Cells and Melanoma Formation: A Common Theme	Prof. Jun Guo Prof. George Coukos	Prof. Lukas Sommer
	Melanoma Treatment Strategy in China		Prof. Jun Guo
	Immunotherapy for Cancer: New Opportunities in Mobilizing Endogenous Immunity and Engineering <i>De Novo</i> Cancer Immunity		Prof. George Coukos
Heterogeneous SNVs/INDELs and Reproducible Copy Number Variation Patterns among Single Circulating Tumor Cells of Lung Cancer Patients	Prof. Jie Wang		
12:00-13:00	Lunch at Cancer Hospital		
13:20-17:50	8 Presentations: 30min/speech (20 min presentation & 10 min Q&A)		
	TITLE	CHAIRS	SPEAKER
	Biobanking as a Prerequisite for Personalized Medicine	Prof. Youyong Lu Prof. Wilhelm Krek	Prof. Holger Moch
	Diagnostic Utility of Embryonic Stem Cell Markers SALL4 and LIN28 in Germ Cell Tumors-Bridging Basic Science and Patient Care		Prof. Dengfeng Cao
	Enhancing Chemotherapy Efficacy in Pten-Deficient Prostate Tumors by Reprogramming the Tumor-Associated Senescence Secretome		Dr. Andrea Alimonti
	PRL-3 Promotes Chromosomal Instability and DNA Damage Response by Targeting RAP1 and TRF2		Dr. Shenyi Lian
	<i>Coffee Break</i>		
	Inferring Tumor Progression Dynamics from Genomic Data	Prof. Youyong Lu Prof. Wilhelm Krek	Prof. Niko Beerenwinkel
	Decreased Fructose-1,6-Bisphosphatase-2 Expression Promotes Glycolysis and Growth in Gastric Cancer Cells		Prof. Youyong Lu
	NMDAR Signaling in Cancer: Regulation by a Polymorphic Modifier Gene and the Tumor Microenvironment	Prof. Youyong Lu Prof. Wilhelm Krek	Dr. Leanne Li
Gastrokine 1 Induces Senescence in Gastric Cancer Cells	Dr. Rui Xing		
17:50	Transfer to Vision Hotel – Speakers only		

CANCER SESSION ON WEDNESDAY, OCTOBER 16, 2013

Venue: 3rd Conference Room, 4th Floor, Scientific Research Building, Peking University Cancer Hospital

07:40	Hotel Pick-up Yuan Liu (+86 188 1077 5516) will meet the delegation at the hotel lobby		
07:40-08:30	Transfer to Peking University Cancer Hospital		
08:30-12:30	7 Presentations: 30 min/speech (20 min presentation & 10 min Q&A)		
	TITLE	CHAIRS	SPEAKER
	Interactions Between Tumor Cells and Lymphatic Endothelium in Cancer Progression	Prof. Yuntao Xie Prof. Ian Frew	Prof. Michael Detmar
	Prevalence and Clinical Implications of BRCA1/2 Germline Mutations in Chinese Women with Breast Cancer		Prof. Yuntao Xie
	The Molecular Basis of Von Hippel Lindau Cancer Syndrome		Prof. Wilhelm Krek
	<i>Coffee Break</i>		
	A Novel Monoclonal Antibody, 1B50-1, Raised Against Recurrent Tumor Cells, Targets $\alpha2\delta1$ and Eliminates Human Liver Tumor-initiating Cells	Prof. Yuntao Xie Prof. Ian Frew	Prof. Zhiqian Zhang
	Decoding Cell Circuits and Processes Through the Application of Multiparametric Life-Cell Imaging- and 3D Tumor Microtissue-Based Screening Approaches		Dr. Claudio Thoma
	MuLE: A New System for Engineering Genetically Complex Tumors in Mice		Dr. Ian Frew
	Cohort Study of HPV Infection and Esophageal Cancer in China		Dr. Fangfang Liu
12:30-13:30	Lunch at Cancer Hospital		
13:30	Transfer to Forbidden City from Cancer Hospital (<i>refer to p.8 for details</i>)		

WEDNESDAY, OCTOBER 16, 2013

13:30	Pick-up from PUHSC & Cancer Hospital - Forbidden City Tour
14:30	Visit Forbidden City—Swiss Delegation Accompanied by Student Volunteers: Xiao Liu +86 150 1141 7207 Xia He +86 186 0076 2715
17:30	Pick-up from Forbidden City--Arranged by OIC
17:30-18:30	Transfer to Houhai Quanjude Restaurant
18:30-20:30	Dinner: Peking Duck
20:30	Transfer to Vision Hotel


WEDNESDAY, OCTOBER 16, 2013

	Airport Pick-up (BA39 09:30 Terminal 3) Arranged by OIC Contact Person: Mengyue Li +86 150 1076 2714
--	--

THURSDAY, OCTOBER 17th, 2013

08:00	Hotel Pick-up - Great Wall Tour Student volunteers will meet the delegation at the hotel lobby: Xiao Liu +86 150 1141 7207 Xia He +86 186 0076 2715
12:30	Pick-up from the Great Wall to the airport (lunch box will be provided)

SPEAKERS AND BIOGRAPHIES



[Adriano Aguzzi, MD, PhD](#)

Director, Institute of Neuropathology, University Hospital of Zurich/Hospital of Zurich

Adriano Aguzzi is the Professor and Director of the Institute of Neuropathology at the University of Zurich. His research career has focused entirely on prions, exploring how they damage brain cells, why they accumulate in lymphoid organs, and how they reach the brain after entering the body from peripheral sites. Prof. Aguzzi has been Associate Dean for Research at the University of Zurich Medical School, and President of the Swiss Society of Neuropathology. He is the Founder and Director of the Swiss National Reference Center for Prion Diseases. Prof. Aguzzi has developed and patented several diagnostic and therapeutic methods in the field transmissible spongiform encephalopathies. He has advised the British, Italian, and Swiss government on spongiform encephalopathies. He sits on the editorial board of the journal “Science” and on the scientific advisory board of various philanthropic foundations and biomedical companies. Among other honors, Prof. Aguzzi has won 2009 the Antonio-Feltrinelli Prize in Rome, as well as the Medal of the European Molecular Biology Organization.



[Andrea Alimonti, MD](#)

Head of the Molecular Oncology Laboratory, Institute of Oncology Research

Dr. Andrea Alimonti is the Head of the Molecular Oncology Laboratory of the Institute of Oncology Research, the research branch of the Oncology Institute of Southern Switzerland (IOSI), and privat-docent in the Faculty of Medicine at the University of Lausanne. Dr. Alimonti received a degree in Medicine from the University of Rome in 2000, and a residency in oncology in 2004 working as clinician at the Italian National Cancer Institute of Rome. He has later worked at the Memorial Sloan Kettering Cancer Center in New York as a post-doctoral research fellow. Subsequently, he spent two years at Harvard Medical School. Dr Alimonti has won several awards including the Swiss Bridge Award and the prestigious ERC starting grant in 2010. He has published many peer-reviewed papers, including papers in Nature, Cell, Nature Genetics, JCI and JCO either as the main or co-author. Dr. Alimonti is a full member of the European Society of Medical Oncology.



Niko Beerenwinkel, PhD

Associate Professor of Computational Biology, Department of Biosystems Science and Engineering, Swiss Federal Institute of Technology, Zurich

Dr. Niko Beerenwinkel was born in Düsseldorf, Germany. He studied mathematics, biology, and computer science, and received his Diploma in Mathematics from the University of Bonn in 1999 and his PhD in Computer Science from Saarland University in 2004. He was a post-doctoral fellow at the University of California at Berkeley (2004-2006) and at Harvard University (2006-2007) before joining ETH Zurich as an Assistant Professor of Computational Biology. Dr. Beerenwinkel's research is at the interface of mathematics, statistics, and computer science with biology and medicine. His interests range from mathematical foundations of biostatistical models to clinical applications. Current research topics include haplotype inference from ultra-deep sequencing data, somatic evolution of cancer, reconstruction of signaling pathways from RNAi screens, HIV drug resistance, graphical models, and algebraic statistics. He has authored over 50 research articles in the areas of computational biology, bioinformatics, biostatistics, virology, and cancer biology. His honors include the Otto Hahn Medal of the Max Planck Society and the Emmy Noether Fellowship of the German National Science Foundation.



Tewis Bouwmeester, PhD

Senior Unit Head, Developmental Molecular Pathways (DMP), Novartis Institutes for Biomedical Research (NIBR)

Dr. Bouwmeester is a trained developmental biologist. He studied Biochemistry in Amsterdam and received his PhD from the Free University of Amsterdam in 1993, and had worked at the Max-Planck Institute for Molecular Genetics in Berlin. He then moved to the University of California at Los Angeles to do a 3-year post-doc stint with Prof. Eddy M. de Robertis working in the area of developmental biology. In 1997, he was recruited to the European Molecular Biology Laboratory (EMBL) in Heidelberg (Germany), where he served on the faculty of the Developmental Biology Department for 4 years. Dr. Bouwmeester is currently the site Head for the Pathways Department and a member of the Basel Scientific Leadership Team. He joined the Novartis Institutes for Biomedical Research in May 2008 from the biotech company Cellzome, where he was VP Biology & Research Alliances. He joined Cellzome in 2001 from the EMBL and held several positions during his tenure.



Dengfeng Cao, MD, PhD

Professor, Department of Anatomic Pathology, Peking University School of Oncology,
Peking University Cancer Hospital, Beijing

Dr. Dengfeng Cao was born in Hunan province, China. He studied pre-medicine in Peking University between 1988 and 1991 and got his MD from Peking Union Medical College in 1996. After graduating from medical school, he went to the University of Pittsburgh to study thermodynamic in protein-DNA interaction and got his PhD in 2001. Dr. Cao completed his residency training in Anatomic and Clinical Pathology in Johns Hopkins Hospital between 2001 and 2005. He then stayed in the Johns Hopkins Hospital for advanced subspecialty training in surgical pathology under the directorship of Dr. Jonathan Epstein between 2005 and 2006, and advanced subspecialty training in Gynecologic pathology with Dr. Robert Kurman between 2006 and 2007. Dr. Cao moved to Washington University School of Medicine & Barnes-Jewish Hospital in 2007 as an assistant professor and attending pathologist. He was promoted to Associate Professors in 2012. During his time in Washington University, Dr. Cao also directed the Research Immunohistochemistry Lab in the Department of Pathology and Immunology. In 2011, Dr. Cao returned to China to head the Department of Anatomic Pathology in Peking University Cancer Hospital. He is currently a full professor and attending pathologist in Peking University. Dr. Cao is an expert pathologist in gynecologic pathology, genitourinary pathology and pancreatic pathology. He is an author for the 4th edition “WHO Classification of Tumours of Female Reproductive Organs” (to be published in 2014) and has authored 60 research articles and currently serves as an editorial board member in four international journals.



George Coukos, MD, PhD

Professor, University of Lausanne/Lausanne University Hospital

Dr. George Coukos is the Director of the Ludwig Cancer Research Center in Lausanne, Switzerland, and the Director of the Department of Oncology at the University Hospital of Lausanne since July 2012. He was previously the Celso Ramon Garcia Professor of Reproductive Biology, Associate Chief of the Division of Gynecologic Oncology, and Director, Ovarian Cancer Research Center, at the University of Pennsylvania Abramson Cancer Center. He is a recognized leader in ovarian cancer immunotherapy and tumor microenvironment research. His research focuses on

understanding the immune system's response to ovarian cancer and other tumor types, and on developing therapies that enhance the immune response. Significant scientific contributions of Dr. Coukos include the discovery of the presence of spontaneous immune responses in ovarian cancer and their impact on clinical outcome, the discovery of mechanisms whereby the tumor vasculature limits T cell trafficking and mediates tumor immune escape, and the discovery of a novel link between tumor hypoxia, regulatory T cell function and tumor angiogenesis. Dr. Coukos's laboratory focuses on engineering immune responses against tumor vasculature and stroma targets, and studying the tumor microenvironment in an effort to optimize therapeutic approaches that exploit endogenous immunity against tumors.



Michael Detmar, MD

Professor of Pharmacogenomics, Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology, Zurich

Dr. Michael Detmar obtained his MD from the University of Freiburg, Germany. He completed his clinical training in dermatology at the Free University of Berlin where he was appointed Assistant Professor of Dermatology in 1991. He was a faculty member at Harvard Medical School from 1993 to 2005. In 1998, he was appointed Associate Professor of Dermatology at the Massachusetts General Hospital and Harvard Medical School in Boston. In 2004, he was appointed Professor of Pharmacogenomics at the ETH Zurich. In 2013, he was elected as a member of the Swiss Research Council.



Dong-Sheng Fan, MD, PhD

Vice Dean, Department of Neurology, Peking University Third Hospital, Beijing

Dr. Dongsheng Fan obtained his license in Neurology from the Third Military Medical College and had his residency in the Department of Neurology at the Second Affiliated Hospital of The Third Military Medical College. He then completed his MS in Neurology at Peking University in China and his PhD in Neurology at Jichi Medical School in Japan. Since then, Dr. Fan has been serving Peking University Third Hospital as an attending doctor, Associated Professor, and now a Professor and Director of the Department of Neurology, as well as the Vice Dean of the hospital.



Patrick Fraering, PhD

Assistant Professor and Merck Serono Chair in Neuroscience, Swiss Federal Institute of Technology-Lausanne (EPFL)

Dr. Patrick Fraering studied biology at the University Louis Pasteur of Strasbourg (France), where he earned a master's degree in biochemistry (1995) and pre-doctoral research degree in molecular and cellular biology at the CNRS (1996). In 2001, he received his PhD, conducting functional studies of the GPI-transamidase complex and protein secretion at the University of Fribourg, Switzerland. In 2002, he had a joint appointment in the labs of Prof. D. Selkoe and Dr. M. Wolfe at Harvard Medical School where he studied Alzheimer's disease and the structure and function of γ -secretase, the protease responsible for the production of the Alzheimer's disease amyloid-peptides. In 2007, he has been appointed assistant professor at the EPFL's School of Life Sciences.



Ian Frew, PhD

Assistant Professor, Institute of Physiology, University of Zurich

Dr. Ian Frew is an Assistant Professor at the Institute of Physiology of the University of Zurich. He obtained his Bachelor of Science degree (Honors) at Australian National University in 1997 and his PhD degree at Peter MacCallum Cancer Centre of the University of Melbourne from 1998 to 2003. He was a post-doctoral fellow at the Institute of Cell Biology of ETH Zurich from 2003 to 2009.



Jun Guo, MD, PhD

Vice President, Peking University School of Oncology, Peking University Cancer Hospital, Beijing

Dr. Jun Guo is a Professor and the Medical Director of the Department of Renal Cancer and Melanoma (which he

helped to establish) in Peking University School of Oncology and Peking University Cancer Hospital. He is a leading researcher in the areas of melanoma and renal cancer in China. He holds multiple positions, such as the President of Chinese Melanoma Committee in Chinese Society of Clinical Oncology, the President of Chinese Renal Cancer Committee in CSCO, member of Global Melanoma Task Force (GMTF). He attended to write “Chinese renal cancer treatment guidelines” and “NCCN guidelines for renal cancer Chinese version”. He is responsible for the “China Melanoma Treatment Guidelines”. He has published many research papers in peer-reviewed journals, such as J Clin Oncol, Clin Cancer Res, Eur J Cancer, Blood, Gene Ther, Int J Cancer, etc.



Sebastian Jessberger, MD, PhD

Co-Director, Brain Research Institute, University of Zurich

Dr. Sebastian Jessberger is a Professor for Neurosciences and the Co-Director of the Brain Research Institute. He studied Medicine in Hamburg, Germany and carried out his medical thesis in the laboratory of Dietmar Kuhl at the Center for Molecular Neurobiology (ZMNH) in Hamburg. In 2002, he started a joint residency in the laboratory of Gerd Kempermann at the MDC and the Department of Neurology of the Charité University Hospital in Berlin, Germany. As a post-doctoral fellow (2004-2007) in the laboratory of Fred H. Gage at the Salk Institute for Biological Studies in La Jolla, USA he continued to work on neural stem cell biology and neurogenesis in the adult brain. From 2007 to 2012, he was an Assistant Professor at the ETH Zurich and joined the Brain Research Institute in August 2012.



Yu Wu Jiang, MD, PhD

Director, Department of Pediatrics, Peking University First Hospital, Beijing

Dr. Yuwu Jiang obtained his MD and PhD from Peking University Health Science Center in 1992 and 1998, respectively. Dr. Jiang furthered his career as a post-doctoral fellow at the Medical School of Johns Hopkins University from August 2003 to June 2005. Dr. Jiang is currently the director and professor of the Department of Pediatrics at Peking University First Hospital and the co-director of the Medical Genetic Center of Peking University Health Science Center. Dr. Jiang also serves as the vice president of the youth committee of the Chinese Pediatric Society and an executive committee member of the Chinese Neuroscience Society.



[Wilhelm Krek, PhD](#)

Chairman of the Institute of Molecular Health Sciences, Swiss Federal Institute of Technology, Zurich

Prof. Wilhelm Krek has been Full Professor of Cell Biology at ETH Zurich since 2003. He was born in 1962 in Klagenfurt, Austria and studied Chemistry at the Technical University Graz. He obtained his PhD in 1991 at the Swiss Cancer Institute in Lausanne, Switzerland. After four years as a postdoctoral fellow at the Dana Farber Cancer Institute/Harvard Medical School in Boston, he worked from 1995-2003 at the Friedrich Miescher Institute (FMI) for Biomedical Research in Basel, Switzerland, first as a Junior Group Leader and START Fellow, and after his promotion in 1999, as a Senior Group Leader. He earned international recognition for his research in the field of cell signaling and cancer and received for his work several prizes including the Robert Wenner Prize and the International Steiner Cancer Research Award. He is an elected member of EMBO and has served as a member of the editorial board of EMBO Journal. Prof. Krek is also the co-founder and Chairman of the Competence Center for Systems Physiology and Metabolic Diseases, a joint center of ETH and University-Hospital Zurich in medical systems biology.



[Hilal Lashel, PhD](#)

Associate Professor, Swiss Federal Institute of Technology-Lausanne (EPFL)


Dr. Hilal A. Lashel was born in the city of Taiz, Republic of Yemen. He received his BSc in chemistry from the City University of New York in 1994 and completed his doctoral studies at Texas A&M University and the Scripps Research Institute in 2000. After obtaining his doctoral degree, he became a research fellow at the Picower Institute for Medical Research in Long Island New York. In 2001, he moved to Harvard Medical School and the Brigham and Women's Hospital as a research fellow in the Center for Neurologic Diseases and was later promoted to an instructor in neurology at Harvard Medical School. During his tenure (2001-2004) at Harvard Medical School his work focused on understanding the mechanisms of protein misfolding and fibrillogenesis and the role of these processes in the pathogenesis of Parkinson's and Alzheimer's disease. In 2005, Dr. Lashel moved to Switzerland to join the Brain Mind Institute at the Swiss Federal Institute of Technology Lausanne as a tenure-track Assistant Professor in Neurosciences. Currently, Dr. Lashel is an Associate Professor of Life Sciences and the Director of the Laboratory of Molecular and Chemical Biology of Neurodegeneration.



Leanne Li, MD

Swiss Institute for Experimental Cancer Research (ISREC), Swiss Federal Institute of Technology-Lausanne (EPFL)

Dr. Leanne Li is currently a PhD student in Swiss Institute for Experimental Cancer Research (ISREC), EPFL. She received her MD in 2008 from Taiwan University, and completed her internship in Taiwan University Hospital. She joined the Hanahan lab in 2009, and since then has been studying the mechanism of tumor progression, especially invasion and metastasis. She was awarded Junior Debiopharm Life Science Award in 2013.



Shenyi Lian, PhD

Department of Biochemistry and Molecular Biology, Peking University School of Oncology, Peking University Cancer Hospital, Beijing

Dr Shenyi Lian is a member of the Biochemistry and Molecular Biology Department of Peking University School of Oncology and Peking University Cancer Hospital. Dr. Lian received a degree in clinical Medicine from the China Medical University in 2007, and a PhD in Biochemistry and Molecular Biology in 2012 at Peking University School of Oncology and Peking University Cancer Hospital.



Dr. Fangfang Liu, PhD

Research Assistant, Peking University School of Oncology, Peking University School of Oncology, Beijing

Dr. Fangfang Liu is currently a Research Assistant at Peking University School of Oncology. She obtained her Bachelor of Preventive Medicine at China Medical University in 2007, and Doctor of Molecular Biology at Peking University School of Oncology in 2012, and has completed the Joint PhD of Epidemiology at School of Public Health, University of Washington from 2010 to 2011. Her research interest is viral infection and the etiology of esophageal cancer.



Dr. Lin Lu, MD, PhD

Director, National Institute on Drug Dependence, Peking University Health Science Center, Beijing

Dr. Lu received his M.D. from North China Coal Medical University in 1999 and completed his PhD at the Institute of Mental Health of West China University of Medical Sciences in 1999. He completed his post-doctoral fellowship at the National Laboratory of Medical Neurobiology at the Shanghai Medical School of Fudan University and the National Institute on Drug Abuse at the National Institutes of Health in Maryland, USA, where he continued as a research scientist. In 2005, Dr. Lu returned to Beijing and served as a director and professor at the National Institute on Drug Dependence at Peking University. Dr. Lu is the councilor of the American Society of Neuroimmune Pharmacology, the chairman of the Chinese Society of Drug Abuse and Dependence, and vice president of the International Chinese Association of Psychiatry. He is also the editor-in-chief of the Chinese Journal of Drug Dependence, an associate editor of Drug and Alcohol Dependence, an editor of PLoS One, and an editorial board member of the International Journal of Mental Health & Addiction and the American Journal of Drug and Alcohol Abuse.



Youyong Lu, MD

Director, Laboratory of Molecular Oncology, Peking University School of Oncology, Peking University Cancer Hospital, Beijing

Dr. Youyong Lu graduated from Inner-Mongolia Medical College with his MD in 1977. Following his advanced training for Medical Science in Beijing Medical University in 1982, he joined as Visiting Fellow and Associate in the Laboratory of Molecular Oncology, NCI/NIH from 1986 to 1990. After that he was appointed as Visiting Scientist in the Department of Medical Oncology, Fox Chase Cancer Center till 1993. Then, he went back to the Department of Biochemistry and Molecular Biology, Beijing Medical University as Associate Professor. Since 1995, Professor Lu has been as Professor and Director of Laboratory of Molecular Oncology in Peking University School of Oncology, Peking University Cancer Hospital.



Holger Moch, MD

Professor of Pathology, University Zurich and Director, Medical Division Pathology and Laboratory Medicine, University Hospital Zurich

Dr. Holger Moch is Professor of Pathology at the University Zurich, Switzerland. He is the Chairman of the Institute for Surgical Pathology as well as Clinical Co-Director in the Department Pathology of the University Hospital Zurich. Dr. Moch is a graduate of the Humboldt University Berlin (Charit é), Germany and completed his residency training at the Institute for Pathology, University Basel, Switzerland. His research program is devoted to the identification of clinically significant biomarkers in cancer as well as the evaluation of novel molecular technologies in surgical pathology. The current research interests are focused on tumor metastasis and VHL -regulated genes. Dr. Moch is a member of the United States and Canadian Academy of Pathology, the editorial board of various journals and boards of several cancer research foundations. He is member of the Executive Committee of the Swiss Group for Clinical Cancer Research (SAKK), the Cancer Network Zurich (CNZ), and the Competence Center for Systems Physiology and Metabolic Diseases (CC-SPMD) of the University Zurich and the Swiss Federal Institute of Technology Zurich (ETH). His work is described in more than 200 peer-reviewed papers. In 2007, he was elected as a member of the German National Academy of Science Leopoldina.



Botond Roska, MD, PhD

Senior Group Leader, Friedrich Miescher Institute for Biomedical Research, Basel

Dr. Botond Roska is the Senior Group Leader of Friedrich Miescher Institute for Biomedical Research. He obtained his MD in 1995 at Semmelweis University of Medicine and PhD in 2002 from the Department of Molecular and Cell Biology of University of California, Berkeley. He was a post-doctoral fellow at the Department of Molecular and Cell Biology of University of California, Berkeley from 1995 to 1997, a Harvard Junior Fellow of Harvard Society of Fellows at Harvard University from 2001 to 2005, and a Junior Group Leader of Friedrich Miescher Institute for Biomedical Research from 2005 to 2010. He was ERC starting investigator in 2010 and EMBO member in 2011, and was awarded Marie Curie Excellence Grant in 2006, EMBO Young Investigator Award in 2009, VIVA Leading Scientist Award in 2010, Alcon Award in 2011, and Alfred Vogt Award in 2013.



Bernard Schneider, PhD

Research Associate, Swiss Federal Institute of Technology-Lausanne (EPFL)

After graduating from the University of Fribourg in Switzerland, Dr. Bernard Schneider has obtained his PhD in Medical Biology at the University of Lausanne in 2001. From 2003 to 2006, he worked as a post-doctoral fellow with Dr. Clive Svendsen at the University of Wisconsin in Madison, USA. Since 2006, he is a senior scientist and project leader at the Brain Mind Institute in the EPFL Life Science Faculty. Dr. Schneider's research focuses on the development of ex vivo and in vivo gene therapy approaches against neurodegenerative diseases. Using viral vectors or cell transplants, he explores means to deliver genetic information to the adult central nervous system for the modeling and treatment of neurodegenerative diseases including Amyotrophic Lateral Sclerosis, Parkinson's and Alzheimer's diseases.



Xue-Jun Song, MD, PhD

Professor, Neuroscience Research Institute, Peking University Health Science Center,
Beijing

Dr. Song obtained his MD (1986) and MS in Anesthesiology (1992) from Xuzhou Medical College, and his PhD in Neurobiology (1995) from the Shanghai Brain Research Institute, Chinese Academy of Sciences. He performed his postdoctoral research in the Department of Anesthesiology at Yale University School of Medicine (1995-1998) and then served as an instructor and a research assistant professor at the University of Texas Medical Center at Houston. Since 1999, Dr. Song has served as an assistant professor, associate professor and professor at Parker University, Dallas, Texas, as well as the director of basic sciences research and the associate director of the Parker Research Institute. In 2012, Dr. Song joined Peking University, Beijing, and served as a professor in the Neuroscience Research Institute and the Department of Neurobiology in the Health Science Center.



Lukas Sommer, PhD

Head of the Division of Cell and Developmental Biology at the Institute of Anatomy,
University of Zurich

Prof. Lukas Sommer carried out his undergraduate studies in Biology at the Biocenter in Basel, Switzerland and received his PhD in 1992 at the Swiss Institute for Experimental Cancer Research (ISREC) in Lausanne, Switzerland. As a post-doctoral fellow in the laboratory of David Anderson at the California Institute of Technology (CALTECH) in Pasadena, California, USA, he began to work on neural crest development and neural stem cell biology. In 1997, Prof. Sommer joined the Institute of Cell Biology at the ETH Zurich, where he first worked as a group leader and then, in 2001, as an Assistant Professor for Cell and Developmental Biology. Since 2007, he is a Full Professor and Head of the Division of Cell and Developmental Biology at the Institute of Anatomy, University of Zurich.



Kelly Tan, PhD

Scientific Collaborator - Ambizione Fellow, University of Geneva Medical School

Dr. Kelly Tan studied neurosciences at the University of Bordeaux, France. She obtained her PhD in Bern, Switzerland for the study of the orientation of benzodiazepines in their GABAA receptor-binding pocket. In 2007, she joined the laboratory of Christian Lüscher in Geneva as a post-doctoral fellow and took advantage of pharmacogenetic and optogenetic tools to dissect the inhibitory circuitries of the reward system. She described how GABA neurons of the ventral tegmental area regulate (VTA) reward and aversion-related learning through the control of the activity of VTA dopamine cells and cholinergic interneurons of the nucleus accumbens. Since October 2013, she is now an Ambizione Fellow at the University of Geneva, Switzerland.



Claudio Thoma, PhD

Institute of Molecular Health Sciences, ETH Zurich

Dr. Claudio Thoma is now a senior scientist at the Institute of Molecular Health Sciences of ETH Zurich. He obtained his PhD at the Laboratory of Prof. Wilhelm Krek of ETH Zurich from 2005 to 2008. He was a post-doctoral fellow in the Laboratory of Prof. Krek from 2008 to 2009, and a post-doctoral fellow at the Laboratory of Prof. S. Elledge of Harvard Medical School from 2010 to 2011.



Jie Wang, MD, PhD

Professor, Chief of Department of Thoracic Oncology, Peking University School of Oncology, Peking University Cancer Hospital, Beijing

Dr. Jie Wang is the Chief of Department of Thoracic Oncology, Peking University School of Oncology and Peking University Cancer Hospital, Beijing, China. After obtaining her PhD in Internal Medicine in 1997 at the West China University of Medical Science, and completed post-doctoral fellowship in oncology in 1999 at Peking University School Oncology, Dr. Wang has been working in Peking University Cancer Hospital as an Associated Professor and Professor. She studied at MD Anderson Cancer Center in USA as Visiting Professor during 2002-2004. Dr. Wang is a member of American Society of Clinical Oncology (ASCO), Chinese Anti-Cancer Association (CACA) and Chinese Medical Association. She is the Executive Committee of Chinese Society of Clinical Oncology (CSCO), and the Standing Committee of the CACA Lung Cancer Profession Committee and Committee Vice –Chairman of Small Cell Lung Cancer Expert Committee.



Kewei Wang, PhD

Professor and Chang Jiang Scholar, Peking University Health Science Center, Beijing

Prof. Kewei Wang graduated with a BA in medicine in 1982 and obtained his PhD in neurophysiology from Beijing Medical University in 1998. He then went to the University of Cambridge and Yale University for post-doctoral training and studies in the areas of ion channel biophysics, physiology and pharmacology. From 1997-2005, Prof. Wang became the team leader and principle research scientist working on ion channel drug discovery and research for new treatments of neurological and neuropsychiatric disorders at Wyeth Pharmaceuticals. In 2005, he was appointed as a Chang Jiang professor of neurobiology at Peking University Health Science Center.



Yun Wang, PhD

Vice Director, Neuroscience Research Institute, Peking University Health Science Center, Beijing

Prof. Yun Wang graduated from Jiangxi Medical College with BA in Medicine, and received her MS in Physiology and PhD in Neurophysiology from Beijing Medical University (merged with Peking University in 2000 and renamed “Peking University Health Science Centre”). From 2000-2002, she worked at the NCI, NIH, as a visiting scientist. Prof. Wang became a professor and the vice director of the Department of Neurobiology in 2004 and the Neuroscience Research Institute in 2009 at Peking University Health Science Center, respectively. Prof. Wang has been the Secretary General of the Chinese Association for Physiological Sciences since 2010.



Charles Weissmann, MD, PhD

Professor Emeritus, Scripps Research Institute, Florida and University of Zurich

Dr. Charles Weissmann obtained his MD degree in 1956 and PhD degree in Organic Chemistry in 1961. He was an Assistant to Professor P. Karrer at University of Zuerich from 1960-1961, a post-doctoral fellow (from 1961-1963), Instructor (from 1963-1964), Assistant Professor (from 1964-1965) and Associate Professor (from 1965-1967) at the NYU School of Medicine, Department of Biochemistry; Professor and Director of the Institute of Molecular Biology, University of Zürich from 1967-1999; Visiting Professor, MRC Prion Unit of London from 1999-2005; Professor and Chairman at the Department of Infectology of Scripps Florida Research Institute from 2004-2012.



Yun Tao Xie, MD, PhD

Professor, Chief of breast cancer research laboratory, Breast Center, Peking University School of Oncology, Peking University Cancer Hospital, Beijing

Dr. Xie received his medical degree in 1986 from the School of Medicine, Wuhan University, China. Since then, as a resident he had been training in general surgery. In 1992, he was a specialist of oncology, working at Zhongnan Hospital, Wuhan University. From 1998 to 2003, as a senior researcher, Dr. Xie studied and worked at Cancer Center Karolinska, Karolinska Institute, Sweden where he mainly focused on the function analysis of SYT-SSX fusion gene. In 2002, he obtained his PhD from the Karolinska Institute. In April 2003, Dr Xie moved to Peking University Cancer Hospital to be the Chief of Breast Cancer Research Laboratory. As a tumor surgeon for breast cancer, Dr. Xie routinely performs operations for breast cancer patients. Meanwhile, he also carries out breast cancer research. Dr. Xie mainly focuses on the translational research of breast cancer. His research interests include (1) the prognostic or predictive markers that sort out the patients who may have a high risk of relapse, or discriminate the patients who may respond to a certain types of neoadjuvant chemotherapy regimens; and (2) Germline mutations in BRCA1/2 or other susceptibility genes in Chinese women with early-onset or familial breast cancer. Dr. Xie has published more than 40 peer-reviewed papers in leading oncology journals, such as J Clin Oncol., JNCI, Cancer Res, Oncogene, and Clin Cancer Res. He currently holds several key research grants for breast cancer research from the Chinese government.



Rui Xing, PhD

Research Assistant, Peking University School of Oncology, Peking University Cancer Hospital, Beijing

Dr. Rui Xing is currently a Research Assistant at the Peking University Cancer Hospital. She obtained her Bachelor degree at Peking University Health Science Center in 2005 and her Doctoral degree at Beijing Institute of Genomics, Chinese Academy of Sciences from 2005 to 2010. She is interested in cancer researches by analyzing genome and proteome.



Albert Cheung Hoi Yu, PhD

Vice Director, Neuroscience Research Institute, Peking University Health Science Center, Beijing


Prof. Albert C.H. Yu received his BSc in Biochemistry, MS in Anatomy and PhD in Pharmacology from the University of Saskatchewan, Canada. He continued to develop his neurobiology research career at the University of California and Stanford University at Palo Alto. Prof. Yu served as a faculty member at the Hong Kong University of Science and Technology before serving his appointment as a Professor at Peking University. Prof. Yu is the Vice Director at the Neuroscience Research Institute of Peking University Health Science Center. He is a Professor and Chief at the Laboratory of Translational Medicine, Institute of System Biomedicine at Peking University, the President of the Beijing Society for Neuroscience and the Vice President of the Chinese Neuroscience Society. Prof. Yu is also the Founder and Chairman of the Hong Kong Biotechnology Organization that aims to facilitate the growth of the biotech industry in Hong Kong and China.



Zhi Qian Zhang, PhD

Professor, Department of Cell Biology, Peking University School of Oncology, Peking University Cancer Hospital, Beijing

Prof. Zhiqian Zhang obtained his PhD in 1997 at Beijing Medical University (now the Peking University Health Center), China, and finished his post-doctoral training at the Department of Cell and Developmental Biology, University of Pennsylvania. His laboratory is interested in the identification and characterization of cells that are responsible for tumor metastasis and/or recurrence, such as so-called cancer stem cells or tumor-initiating cells. By employing comparative global gene expression analysis and functional screening, his laboratory is devoted to understand the molecular mechanisms involved in the regulation of the drug resistance, invasion and metastasis, tumorigenicity, and self-renewal properties of these cells. They hope that these studies will eventually lead to the identification of some molecules that can potentially be used as prognostic biomarkers and/or therapy targets. His laboratory recently has identified the isoform 5 of the voltage-gated calcium channel $\alpha 2\delta 1$ subunit as a novel liver tumor-initiating cell marker and therapeutic target.



Caihong Zhu, Ph.D.

Post-doctoral Fellow, Institute of Neuropathology, University Hospital Zurich

Dr. Caihong Zhu is now a post-doctoral fellow at the Institute of Neuropathology of University Hospital Zurich. He graduated from Anhui Polytechnic University as a Bachelor student in 2003, obtained his Master and Doctoral degrees from Tongji University from 2004-2009.

ACKNOWLEDGEMENT

This symposium was supported by “Biomedical International Cooperation Fund” donated by Mr. Tang Yau Choi (邓佑才先生). We sincerely thank Mr. Tang for his contribution to promote the progress of biomedical exchange and cooperation between China and Switzerland.

Notes:



Peking University Health Science Center

38 Xue Yuan Road

100191 Beijing

China

Sino Swiss Science and Technology Cooperation

ETH Global (EG), ETH Zürich

Rämistrasse 101

8092 Zürich

Switzerland